Pediatric Oncology, Clinical Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Blood. 2011 Jun 9;117(23):6083-90. doi: 10.1182/blood-2011-01-283606. Epub 2011 Mar 23.
Despite progress in our understanding of the growth factors that support the progressive maturation of the various cell lineages of the hematopoietic system, less is known about factors that govern the self-renewal of hematopoietic stem and progenitor cells (HSPCs), and our ability to expand human HSPC numbers ex vivo remains limited. Interest in stem cell expansion has been heightened by the increasing importance of HSCs in the treatment of both malignant and nonmalignant diseases, as well as their use in gene therapy. To date, most attempts to ex vivo expand HSPCs have used hematopoietic growth factors but have not achieved clinically relevant effects. More recent approaches, including our studies in which activation of the Notch signaling pathway has enabled a clinically relevant ex vivo expansion of HSPCs, have led to renewed interest in this arena. Here we briefly review early attempts at ex vivo expansion by cytokine stimulation followed by an examination of our studies investigating the role of Notch signaling in HSPC self-renewal. We will also review other recently developed approaches for ex vivo expansion, primarily focused on the more extensively studied cord blood-derived stem cell. Finally, we discuss some of the challenges still facing this field.
尽管我们在理解支持造血系统各种细胞谱系渐进成熟的生长因子方面取得了进展,但对于控制造血干细胞和祖细胞(HSPC)自我更新的因素知之甚少,我们体外扩增人类 HSPC 数量的能力仍然有限。由于 HSCs 在治疗恶性和非恶性疾病中的重要性日益增加,以及它们在基因治疗中的应用,人们对干细胞扩增的兴趣日益浓厚。迄今为止,大多数体外扩增 HSPC 的尝试都使用了造血生长因子,但并未达到临床相关的效果。最近的方法,包括我们的研究,其中 Notch 信号通路的激活使 HSPC 的体外扩增具有临床相关性,这重新引起了人们对这一领域的兴趣。在这里,我们简要回顾了早期通过细胞因子刺激进行体外扩增的尝试,然后检查了我们研究 Notch 信号在 HSPC 自我更新中的作用的研究。我们还将回顾其他最近开发的体外扩增方法,主要集中在研究更广泛的脐带血衍生干细胞上。最后,我们讨论了该领域仍面临的一些挑战。